Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M.M. Eggermont, Ulrich Keilholz, Alan Spatz et al.|The Lancet|2008Cited by 642
Thin Stage I Primary Cutaneous Malignant MelanomaUmberto Veronesi, K. Wozniak, Natale Cascinelli et al.|New England Journal of Medicine|1988Cited by 564
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialAlexander M.M. Eggermont, Danielle Líénard, Stefan Suciu et al.|The Lancet|2005Cited by 314
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trialNatale Cascinelli, Alberto Morabito, Filiberto Belli et al.|The Lancet|2001Cited by 251
Genome-wide association study identifies three new melanoma susceptibility lociJennifer H. Barrett, Joan Anton Puig‐Butille, Mark M. Iles et al.|Nature Genetics|2011Cited by 250